Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN23 in Pediatric XLH
NCT03233126Phase 3Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2017
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of burosumab in X-linked hypophosphatemia (XLH), sponsored by Kyowa Kirin. Primary endpoints: Number of subjects for each adverse events and Percentage of subjects for each adverse events. Started Jul 2017; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphatemia (XLH)
Beyond the preview
Go deeper on NCT03233126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233126.